Logo

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Share this

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Shots:

  • The first patient has been dosed in a P-II clinical trial evaluating the efficacy and safety of IBI362 (GLP-1R and GCGR dual agonist) in a patient with overweight or obese in China
  • The 1EPs of the study are to evaluate the change from baseline in body weight @24 wks.- and to recommend the optimal dose for P-III studies
  • The P-I study for IBI362 demonstrates a good safety profile and has the potential for clinically- weight loss- and multiple metabolic benefits. Innovent has entered into a licensing agreement with Eli Lilly for the development and commercialization of OXM3 in China while Lilly is developing OXM3 (Ex- China)

  | Ref: Business Wire | Image:  Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions